'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

By determining a safe dosing regimen for Child-Pugh B and C patients, FDA was able to provide a label almost completely without contraindications despite safety concerns about liver-related adverse reactions.